Equities

Protagonist Therapeutics Inc

PGF:BER

Protagonist Therapeutics Inc

Actions
  • Price (EUR)43.20
  • Today's Change-0.600 / -1.37%
  • Shares traded36.00
  • 1 Year change+189.93%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 20:52 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
OPERATIONS
Net income(79)(127)(126)
Depreciation/depletion0.981.030.81
Non-Cash items272620
Cash taxes paid, supplemental000
Cash interest paid, supplemental------
Changes in working capital(20)(7.77)(3.31)
Total cash from operations(70)(108)(108)
INVESTING
Capital expenditures(0.61)(0.8)(1.1)
Other investing and cash flow items, total(39)92(15)
Total cash from investing(39)91(16)
FINANCING
Financing cash flow items(0.77)(0.16)(0.19)
Total cash dividends paid------
Issuance (retirement) of stock, net17119130
Issuance (retirement) of debt, net--0--
Total cash from financing17019130
NET CHANGE IN CASH
Foreign exchange effects0(0.09)(0.13)
Net change in cash612.086.07
Net cash-begin balance/reserved for future use126124118
Net cash-end balance/reserved for future use187126124
SUPPLEMENTAL INCOME
Depreciation, supplemental0.981.030.81
Cash interest paid, supplemental------
Cash taxes paid, supplemental000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.